Form 8-K · Current Report · Filed 2025-08-19
Edwards Lifesciences Announces Accelerated Share Repurchase Agreement
On August 19, 2025, Edwards Lifesciences Corporation announced the entry into an accelerated share repurchase agreement, as detailed in its press release.
- Filer
- Edwards Lifesciences Corporation EW · NYSE
- Filed
- Accession
- 0001099800-25-000056
- CIK
- 0001099800
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The specific terms of the agreement are to be found in the filed exhibit 99.1, which is incorporated by reference.
Items reported
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$78.30
Next session
+3.9%
Since filing
+9.9%
Latest close
$86.07
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from EW reporting the same item, with the next session's move:
Exhibits (1)
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.
Never miss another EW filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.